Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion (2016 - 2025)

Amphastar Pharmaceuticals has reported Depreciation and Depletion over the past 13 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Depreciation and Depletion at $8.1 million for Q4 2025, up 11.22% from a year ago — trailing twelve months through Dec 2025 was $31.6 million (up 12.03% YoY), and the annual figure for FY2025 was $31.6 million, up 12.03%.
  • Depreciation and Depletion for Q4 2025 was $8.1 million at Amphastar Pharmaceuticals, up from $7.9 million in the prior quarter.
  • Over the last five years, Depreciation and Depletion for AMPH hit a ceiling of $8.3 million in Q2 2025 and a floor of $5.4 million in Q3 2021.
  • Median Depreciation and Depletion over the past 5 years was $6.3 million (2023), compared with a mean of $6.6 million.
  • Peak annual rise in Depreciation and Depletion hit 20.57% in 2021, while the deepest fall reached 2.69% in 2021.
  • Amphastar Pharmaceuticals' Depreciation and Depletion stood at $5.4 million in 2021, then grew by 14.62% to $6.2 million in 2022, then grew by 7.37% to $6.6 million in 2023, then grew by 9.28% to $7.3 million in 2024, then increased by 11.22% to $8.1 million in 2025.
  • The last three reported values for Depreciation and Depletion were $8.1 million (Q4 2025), $7.9 million (Q3 2025), and $8.3 million (Q2 2025) per Business Quant data.